Skip to content

新闻稿

大乐透1000期走势图:Illumina Names Dr. Phil Febbo Chief Medical Officer

超级大乐透中奖规则 www.slf2t.cn

Brings unmatched bench-to-bedside expertise to catalyze the adoption of precision medicine

SAN DIEGO--(BUSINESS WIRE)--Mar. 12, 2018-- Illumina, Inc.?(NASDAQ:ILMN) announced?today the appointment of Dr. Phil Febbo, a leading physician scientist, as Chief Medical Officer (CMO), starting March 26, 2018. In his new role, Dr. Febbo will be responsible for developing and executing on the Company’s medical strategy to drive genomic testing into healthcare practice.

This press release features multimedia. View the full release here://www.businesswire.com/news/home/20180312006000/en/

Illumina names Dr. Phil Febbo Chief Medical Officer - Brings unmatched bench-to-bedside expertise to ...

Illumina names Dr. Phil Febbo Chief Medical Officer - Brings unmatched bench-to-bedside expertise to catalyze the adoption of precision medicine. (Photo: Business Wire)

“We are very excited to welcome Dr. Febbo, who comes to us at a transformative time in the evolution of genomic medicine,” said Garret Hampton, Ph.D., Executive Vice President of Clinical Genomics at Illumina. “Phil brings a wealth of clinical and scientific experience to Illumina, from understanding the genomic basis of common human cancers, to the development of clinical tests based on next generation sequencing. We believe that his experience will ensure that Illumina is uniquely positioned to change medical practice with the use of genomics.”

For the past 25 years, Dr. Febbo has worked at leading institutions throughout the United States, most recently serving as CMO of Genomic Health (NASDAQ:GHDX). Prior to joining Genomic Health, Dr. Febbo served as Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. While at UCSF, Dr. Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology.

Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at UCSF, and completed his internal medicine residency at the Brigham and Women’s Hospital. After his fellowship in medical oncology at the Dana-Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). In 2004, Dr. Febbo moved to Duke University Medical Center’s Institute of Genome Sciences and Policy. He has been a member of the American Society for Clinical Investigation since 2009.

About Illumina

Illumina?is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets.?Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit?www.illumina.com?and follow @illumina.

Use of forward-looking statements

This release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to further develop and commercialize our instruments and consumables, and to deploy new products, services and applications, and expand the markets for our technology platforms; (ii) our ability to manufacture robust instrumentation and consumables; (iii) our ability to successfully identify and integrate acquired technologies, products or businesses; (iv) the future conduct and growth of the business and the markets in which we operate; and (v) challenges inherent in developing, manufacturing, and launching new products and services, together with other factors detailed in our filings with the?Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Jacquie Ross, CFA
858-882-2172
[email protected]
or
Media:
Lisa Warshaw
323-360-8778
[email protected]

Recent Articles

Alt text for article
遗传性肾病是中国新合作中的重点领域
Alt text for article
Video: Francis deSouza Speaks at the 16th Annual Precision Medicine World Conference
Alt text for article
University of Melbourne and Illumina Drive Genomics Innovation in Australia
  • 法国总统马克龙首次访华 法国居民期待成果 2019-06-08
  • 土耳其海军真会享受, 万吨巨舰上有个露天游泳池 2019-06-08
  • 肝脏-热门标签-华商生活 2019-05-22
  • 苏宁控股集团获第十二届人民企业社会责任奖年度企业奖 2019-05-19
  • 上海:高校课程思政领航计划启动 2019-05-19
  • 江报直播室:两会谈“新”录 2019-05-07
  • 哪个不在痛打落水狗呢 2019-05-07
  • “中国网事·感动2017” 年度网络人物评选专家评审会在京召开 2019-05-01
  • 这家央企的员工为何这么拼? 2019-05-01
  • 自治区党委召开常委(扩大)会议 陈全国主持 2019-04-12
  • 新时代的主要矛盾是需要与发展不充分不平衡的矛盾,发展不充分的原因在于历史的欠账,近代的落后,发展的不平衡的原因应该归功于市场经济。 2019-04-12
  • 承认私有制存在,却否认阶级分析。睁着眼睛说瞎话,强坛独一份。 2019-04-02
  • 回复@老老保老张工:你肯定有咱无法企及的本事!比如你可以不要脸,咱就不行。 2019-04-01
  • 违法和不良信息举报受理和处置管理办法 2019-04-01
  • 人民日报开放谈:服务开放好处多 2019-03-31
  • 177| 70| 229| 612| 116| 950| 978| 40| 304| 670|